MP51-14 A COMPARISON OF 111IN-J591 SPECT WITH 89ZR-J591 PET IMAGING FOR PROSTATE CANCER PATIENTS. (2014)

You have accessJournal of UrologyProstate Cancer: Localized V1 Apr 2014MP51-14 A COMPARISON OF 111IN-J591 SPECT WITH 89ZR-J591 PET IMAGING FOR PROSTATE CANCER PATIENTS. Sandhya Chalasani, Shoaib Fareedy, Sarah Lindgren-Belal, Daniel Spratt, Brian Robinson, Joseph Osborne, Neil Bander, and Douglas Scherr Sandhya ChalasaniSandhya Chalasani More articles by this author , Shoaib FareedyShoaib Fareedy More articles by this author , Sarah Lindgren-BelalSarah Lindgren-Belal More articles by this author , Daniel SprattDaniel Spratt More articles by this author , Brian RobinsonBrian Robinson More articles by this author , Joseph OsborneJoseph Osborne More articles by this author , Neil BanderNeil Bander More articles by this author , and Douglas ScherrDouglas Scherr More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1670AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Introduction and Objectives To compare pilot cohorts of men scheduled for radical prostatectomy imaged with novel antibody conjugates: Cohort 1 (111In-J591) single photon emission tomography (SPECT) or Cohort 2 (89Zr-J591) positron emission tomorgraphy (PET). Methods 1) Cohort 1: Eight patients with abnormal digital rectal exam and biopsy proven prostate cancer were injected intravenously with two milligrams of J591 labeled with 5mCi of 111In. SPECT/CT imaging was performed 2 to 5 days post injection. Prostatectomy was performed on the day of imaging and the excised prostate was imaged with SPECT/CT and planar scintigraphy before being sent to surgical pathology. 2) Cohort 2: Eleven patients were injected intravenously with 5mCi 89Zr-J591 followed 6 days later by whole body PET imaging. Patients underwent surgery the day of PET imaging and the specimens were imaged by ex vivo PET and custom 3 Tesla magnetic resonance scanner coil. SPECT/ PET imaging studies and histopathology were correlated. Results 111In-J591 whole body images showed the expected bio-distribution seen in other ongoing imaging/therapy trials for metastatic Prostate Cancer (PCa). Imuno-scintigraphic images were consistent with the pathologic diagnoses for all of the patients. In case of 89Zr-J591/PSMA PET imaging in localized PCa it is observed 89Zr-J591-PET binds to tumor foci in situ and binds primarily to Gleason ≥7 and larger sized tumors, likely corresponding to clinically significant disease that warrants definitive therapy. Conclusions 111In-J591 demonstrated targeting in localized disease in prostatectomy specimen, but pathologic validation was only inferred by quadrant due to low soft tissue contrast and the inherent resolution limits of the clinical scanner on a relatively small specimen. 89Zr-J591-PET can identify discrete intra-prostatic tumor foci, and in our cohort, visualized most of the index lesions. Additionally, high-grade tumors are generally better visualized with this novel imaging agent. There is a relationship between SUV on the 89Zr-J591-PET of tumor foci and their aggressiveness as defined by Gleason score. The preliminary data from this pilot study warrants further investigation with MicroSPECT and autoradiograph or ImmunoPET and MRI. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e602-e603 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Sandhya Chalasani More articles by this author Shoaib Fareedy More articles by this author Sarah Lindgren-Belal More articles by this author Daniel Spratt More articles by this author Brian Robinson More articles by this author Joseph Osborne More articles by this author Neil Bander More articles by this author Douglas Scherr More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...